Takeda Bolsters Gastrointestinal Franchise with Acquisition of Ex-US Rights to Cx601
By Dan Roberts
Pharma Deals Review: Vol 2016 Issue 7 (Table of Contents)
Published: 26 Jul-2016
DOI: 10.3833/pdr.v2016.i7.2177 ISSN: 1756-7874
Section: Licensing
Fulltext:
Abstract
In order to broaden its portfolio for Crohn’s disease, Takeda has agreed to acquire the ex-US rights to Cx601 from the Belgian company,TiGenix...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS